CHICAGO--(BUSINESS WIRE)--Use of TYRX, Inc.’s AIGISRx® Antibacterial Envelope significantly reduced infection rates in patients undergoing pacemaker and implantable defibrillator implants, who were at high risk of surgical infections, according to a study presented today at the American College of Cardiology 61st Annual Scientific Session in Chicago, IL.
